Di- and Triselenoesters—Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147764 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Dominika Radomska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Apoptosis, Cell Proliferation, Autophagy, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok, Medical University of Bialystok.
Abstract (Originalsprache)
Breast cancer is a major malignancy among women, characterized by a high mortality rate. The available literature evidence indicates that selenium, as a trace element, has chemopreventive properties against many types of cancer; as such, compounds containing it in their structure may potentially exhibit anticancer activity. Accordingly, we have undertaken a study to evaluate the effects of novel selenoesters (EDAG-1, -7, -8, -10) on MCF-7 and MDA-MB-231 breast cancer cells. Our analysis included investigations of cell proliferation and viability as well as cytometric determinations of apoptosis/autophagy induction, changes in mitochondrial membrane polarity (ΔΨm), caspase 3/7, 8, and 9 activities, and Bax, Bcl-2, p53, Akt, AMPK, and LC3A/B proteins. The obtained data revealed that the tested derivatives are highly cytotoxic and inhibit cell proliferation even at nanomolar doses (0.41–0.79 µM). Importantly, their strong proapoptotic properties (↑ caspase 3/7) are attributable to the effects on both the extrinsic (↑ caspase 8) and intrinsic (↓ ΔΨm and Bcl-2, ↑ Bax, p53, and caspase 9) pathways of apoptosis. Moreover, the tested compounds are autophagy activators (↓ Akt, ↑ autophagosomes and autolysosomes, AMPK, LC3A/B). In summary, the potent anticancer activity suggests that the tested compounds may be promising drug candidates for future breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Department of Medicinal Chemistry, Medical University of Bialystok, Mickiewicza 2D, 15-222 Bialystok, Poland.
- Instituto de Química Orgánica General (IQOG-CSIC), Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain.
- Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
ORCID-Profile: Dominika Radomska, Robert Czarnomysy, Anna Szymanowska, Arkadiusz Surazynski, Enrique Domínguez-Álvarez, Krzysztof Bielawski
Förderung
- Medical University of Białystok
- Medical University of Bialystok
Zitieren
APA
Radomska, D., Czarnomysy, R., Szymanowska, A., Radomski, D., Chalecka, M., Surazynski, A., Domínguez-Álvarez, E., Bielawska, A., & Bielawski, K. (2024). Di- and Triselenoesters—Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147764
Vancouver
Radomska D, Czarnomysy R, Szymanowska A, Radomski D, Chalecka M, Surazynski A, et al. Di- and Triselenoesters—Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147764
BibTeX
@article{Radomska2024,
author = {Radomska, Dominika and Czarnomysy, Robert and Szymanowska, Anna and Radomski, Dominik and Chalecka, Magda and Surazynski, Arkadiusz and Domínguez-Álvarez, Enrique and Bielawska, Anna and Bielawski, Krzysztof},
title = {Di- and Triselenoesters—Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147764}
}
EUVIMED